BioNTech Starts Phase 3 Trial of Pumitamig Plus Gilead's Trodelvy for Breast Cancer

By Reuters News

- BIONTECH SE 22UAy.DE:

  • ADVANCES PHASE 3 CLINICAL TRIAL OF PUMITAMIG IN COMBINATION WITH GILEAD’S TROP2-DIRECTED ADC SACITUZUMAB GOVITECAN IN TRIPLE-NEGATIVE BREAST CANCER

  • CO AND GILEAD TO EVALUATE PUMITAMIG WITH SACITUZUMAB GOVITECAN IN FIRST-LINE TNBC

  • ROSETTA BREAST-01 PHASE 3 TRIAL EVALUATES PUMITAMIG IN TRIPLE-NEGATIVE BREAST CANCER

  • UNDER TERMS OF AGREEMENT, BIONTECH WILL CONTINUE TO SPONSOR AND LEAD ROSETTA BREAST-01 TRIAL

  • GILEAD WILL SUPPLY SACITUZUMAB GOVITECAN FOR COMBINATION TRIAL

Further company coverage: [22UAy.DE]

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk